| Literature DB >> 31440730 |
Camilo Espinosa-Jovel1,2, Rafael Toledano2,3, Adolfo Jiménez-Huete4, Ángel Aledo-Serrano2, Irene García-Morales2,5, Pablo Campo6, Antonio Gil-Nagel2.
Abstract
Several lines of research have linked olfactory regions with the pathophysiology of focal epilepsies. Among those regions, the piriform cortex represents the major part of the primary olfactory cortex. According to these data, we raised the hypothesis that in patients with mesial temporal lobe epilepsy associated with hippocampal sclerosis exists an interictal dysfunction of olfactory processing that could be more significant compared to patients with extra-hippocampal focal epilepsy and healthy controls. This could be the consequence of a dysfunctional epileptogenic network that extends beyond the hippocampus and affects other structures, including the piriform cortex. To test this hypothesis, we evaluated the olfactory function with the Sniffin' Sticks test in 32 patients with mesial temporal lobe epilepsy associated with hippocampal sclerosis, 30 patients with extra-hippocampal focal epilepsy, and 22 healthy controls. Compared to the other study groups, patients with temporal lobe epilepsy due to hippocampal sclerosis showed a basal olfactory dysfunction characterized by an impairment in odor discrimination and odor identification. We also found that high seizure frequency had a strong correlation with the evaluated olfactory tasks. Our results are consistent with neuroimaging and neuropathological data that establish a link between olfactory regions and the pathophysiology of temporal lobe epilepsy.Entities:
Keywords: epilepsy; hippocampal sclerosis; olfaction; piriform cortex; temporal lobe
Year: 2019 PMID: 31440730 PMCID: PMC6698687 DOI: 10.1002/epi4.12343
Source DB: PubMed Journal: Epilepsia Open ISSN: 2470-9239
Demographic and clinical variables.
| Hippocampal epilepsy | Extra‐hippocampal epilepsy | Healthy controls | Test | P value | |
|---|---|---|---|---|---|
| Total | 32 | 30 | 22 | – | – |
| Age, median (IQR) | 44.5 (37.5‐52) | 32.5 (25‐46) | 42.5 (34.5‐46) | ANOVA | 0.004 |
| Duration of disease, median (IQR) | 28.5 (15.8‐38.2) | 13.5 (10‐22.8) | ‐ |
| 0.001 |
| Sex frequency (percentage) | |||||
| Female | 14 (43.8) | 12 (40) | 11 (50) | Chi‐square test | 0.772 |
| Male | 18 (56.2) | 18 (60) | 11 (50) | ||
| Type of seizures, frequency (percentage) | |||||
| Focal without impairment of consciousness | 8 (25) | 17 (56.7) | ‐ | Fisher's exact test | 0.019 |
| Focal with impairment of consciousness | 23 (71.9) | 13 (43.3) | |||
| Generalized | 1 (3.1) | 0 (0) | |||
| History of status epilepticus, frequency (percentage) | |||||
| Yes | 1 (3.1) | 5 (16.7) | ‐ | Fisher's exact test | 0.099 |
| No | 31 (96.9) | 25 (83.3) | |||
| Febrile seizures, frequency (percentage) | |||||
| Yes | 8 (25) | 0 (0) | ‐ | Fisher's exact test | 0.005 |
| No | 24 (75) | 30 (100) | |||
| Seizure frequency in the last year, frequency (percentage) | |||||
| No seizures | (6.2) | 4 (13.3) | ‐ | Fisher's exact test | 0.88 |
| 1‐3 | 7 (21.9) | 4 (13.3) | |||
| 4‐6 | 4 (12.5) | 4 (13.3) | |||
| 7‐9 | 2 (6.2) | 2 (6.7) | |||
| ≥10 | 17 (53.1) | 16 (53.3) | |||
| Laterality of the lesion, frequency (percentage) | |||||
| Left | 19 (59.4) | 19 (63.3) | ‐ | Fisher's exact test | 0.99 |
| Right | 11 (34.4) | 10 (33.3) | |||
| Bilateral | 2 (6.2) | 1 (3.3) | |||
| Number of antiepileptic drugs, frequency (percentage) | |||||
| 1 | 4 (12.5) | 8 (26.7) | ‐ | Fisher's exact test | 0.008 |
| 2 | 18 (56.2) | 10 (33.3) | |||
| 3 | 5 (15.6) | 12 (40) | |||
| ≥4 | 5 (15.6) | 0 (0) | |||
Association between study group and olfactory variables
| Hippocampal epilepsy | Extra‐hippocampal epilepsy | Healthy controls | Crude | Adjusted | Post hoc analysis | |
|---|---|---|---|---|---|---|
| Olfactory threshold, median (IQR) | 6.5 (5.6‐6.7) | 7.5 (6.3‐8.4) | 8.5 (7.1‐10) | <0.001 | 0.12 | – |
| Odor discrimination, median (IQR) | 9 (8‐10.2) | 11 (10‐12) | 14 (13.2‐15) | <0.001 | <0.001 |
EH‐C = 0.76 |
| Odor identification, median (IQR) | 10 (10‐11) | 12 (11‐12) | 14 (13‐14) | <0.001 | <0.001 |
EH‐C = 0.705 |
| TDI score, median (IQR) | 26.1 (22.6‐28.3) | 29.8 (28.3‐32.2) | 36.5 (35.5‐37.8) | <0.001 | <0.001 |
EH‐C = 0.64 |
Adjustment variables: age, sex, seizure frequency, and duration of disease. Variables excluded due to high collinearity: laterality of the lesion and number of antiepileptic drugs.
Abbreviations: C, healthy control; EH, extra‐hippocampal epilepsy; H, hippocampal epilepsy.